The purinergic receptor P2X ligand-gated ion channel 7 (P2X7 receptor) is a promising imaging target to detect neuroinflammation. Herein, we report development of a potent iodinated radiotracer for P2X7 receptor, has an IC 50 value of 9.49 ± 1.4 nM, and the known P2X7 receptor compound GSK1482160 has an IC 50 value of 4.30 ± 0.86 nM, consistent with previous reports. The radioligand saturation binding assay and competitive assay revealed that [ 123 I]TZ6019 specifically bound to the human P2X7 receptor with high affinity (K i = 6.3 ± 0.9 nM). In vitro autoradiography quantification with brain slices collected from 9-month old P301S tau transgenic mice along with wild type controls, revealed higher binding of [ 123 I]TZ6019 (35% increase) in the brain of P301S transgenic mice (n = 3, p = 0.04) compared to wild type controls. The immunofluorescence microscopy confirmed that expression of P2X7 receptor was colocalized with astrocytes in the tauopathy P301S transgenic mice. [ 123 I]TZ6019 has specific binding for P2X7 receptor and has great potential to be a radiotracer for screening new compounds and quantifying expression of P2X7 receptor in neuroinflammation related diseases.
Introduction
Neuroinflammation plays an important role in progression of many neurodegenerative diseases including Alzheimer disease (AD) and Parkinson disease (PD) (Bhattacharya and Biber, 2016; Monif et al., 2010) . Elevated purinergic receptors expression has shown close association with neuroinflammation due to the large release of adenosine/ uridine derivatives from the damage site (Bhattacharya et al., 2013; Boumechache et al., 2009) . Purinergic receptors are adenosine-triphosphate (ATP) gated non-selective ion channels which are expressed on the surface of many different cell types (Able et al., 2011; Burnstock, 2009a Burnstock, , 2009b . Among these purinergic receptors, P2X7 receptor has been implicated in microglial activation, astrogliosis, or phagocytosis at sites of injury (Bartlett et al., 2014; Bhattacharya and Biber, 2016; Franke and Illes, 2014; Grygorowicz et al., 2016) , and release of proinflammatory cytokines (Bianco et al., 2006; Collo et al., 1997; Ferrari et al., 2006) . Upregulation of extracellular ATP in neuroinflammatory conditions significantly increases expression of P2X7 receptor. The P2X7 receptor knockout mice display a significantly reduced neuroinflammatory response (Basso et al., 2009; Monif et al., 2009) . Therefore, P2X7 receptor represents a novel molecular target for imaging and treating neuroinflammation in neurological diseases. A potent P2X7 receptor antagonist, GSK1482160, has recently been labeled with carbon-11 (half-life 20.4 min) for positron emission tomography (PET) imaging of neuroinflammation in an animal model (Gao et al., 2015; Han et al., 2017; Ory et al., 2016) . However, this radioligand showed tight binding to human P2X7 receptor, but weak binding to rodents P2X7 receptor (Gao et al., 2015; Ory et al., 2016) . And the human applications of this tracer remain to be explored. New potent ligands specifically targeting both human and rodent P2X7 receptor, and capable to be translated for clinic are still in demand. Screening new analogues for P2X7 ligand development requires a reliable assay platform for P2X7 receptor. For the in vitro assays, labeled probes with longer half-life radioisotopes facilitate implementation of these assays. and the binding of P2X7 receptor was associated with the neuroinflammation in the tauopathy mouse model.
Materials and methods

Chemistry
The structures of several known P2X7 receptor radioligands including [
123 I]TZ6019 are summarized in Fig. 1 . Compound GSK1482160 was synthesized by following the reported procedure (Gao et al., 2015; Han et al., 2017) . The standard compound 5 (TZ6019) was also synthesized from demethyl-GSK1482160, depicted in Scheme 1A. All reagents and chemicals were obtained from standard commercial sources and used without further purification, unless otherwise stated. The organic reaction was carried out under inert nitrogen and moisture-free conditions with a dry solvent. Thin layer chromatography (TLC) was used to monitor the reaction with precoated glass plates of silica gel 60 F 254 from EMD Chemicals Inc.
(Gibbstown, NJ). The product of each step was purified by silica gel 40-63 µm from SiliCycle Inc. (Quebec City, Quebec, Canada).
1
H and 13 C spectra were recorded at 400 MHz on a Varian Mercury-VX spectrometer with CDCl 3 as solvents and tetramethylsilane (TMS) as the internal standard. The chemical shifts were reported in δ (ppm) values relative to CHCl 3 (δ 7.26 ppm for 1 H NMR and δ 77.2 ppm for 13 C NMR), multiplicities were indicated by s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and br (broad). High resolution mass spectrum (HRMS) was performed on a Waters ZQ 4000 single quadrupole mass spectrometer equipped with an electrospray ionization (ESI) LC-MS interface.
At 0°C, 3 ml Lithium bis(trimethylsilyl)amide (LiHMDS, 1 M in tetrahydrofuran, THF) was added into an oven-dried 100 ml round bottle flask with a solution of compound 3 (600 mg, 1.8 mmol, 1.0 equiv.) in 10 ml dimethylformamide (DMF) (Gao et al., 2015; Han et al., 2017) . Then 2.0 equiv. of tributyl-(3-chloro-propenyl)-stannane was added into the flask at 0°C. The mixture was stirred overnight at room temperature, then extracted with ethyl acetate (EtOAc). The organic solution was dried using Mg 2 SO 4 , filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column using hexane/EtOAc (1/1, v/v) to yield product 4 as a yellow solid (320 mg, 27% yield 
A solution of iodine in chloroform (0.1 M, 2 ml) was added dropwise to a solution of 4 (130 mg, 0.2 mmol) in dry chloroform (10 ml). The reaction was stirred at room temperature for 20 h. The solution then was diluted with chloroform (15 ml), washed with saturated Na 2 S 2 O 3 (6 × 25 ml) and then saturated aqueous NaCl solution. The combination of organic layers were dried over anhydrous sodium sulfate, concentrated under reduced pressure. The residue was purified by flash silica gel chromatography using hexane/EtOAc (1/4, v/v) as the eluent to yield the final product 5 (TZ6019) in a brown solid (86 mg, 88% yield). 1 H NMR (400 MHz, CDCl 3 ): δ 7.62 (d, J = 7.7 Hz, 1H), 7.53 (d, J = 7.5 Hz, 1H), 7.32 (t, J = 7.8 Hz, 1H), 6.67 (t, J = 5.5 Hz, 1H), 6.42-6.24 (m, 1H), 6.18 (d, J = 14.7 Hz, 1H), 4.64-4.44 (m, 2H), 4.14 (dd, J = 14.9, 5.2 Hz, 1H), 3.99 (dd, J = 8.5, 3.6 Hz, 1H), 3.31 (dd, J = 15.3, 7.9 Hz, 1H) 
Compound 6 (TZ5038) was prepared similarly to compound 4. Compound 6 white solid (360 mg, 54% yield) was derived from compound 3 (600 mg, 1.8 mmol, 1.0 equiv.) and 1-bromo-2-fluoroethane (2.0 equiv. Canada) was added to a mixture of tin-precursor 4 (300-400 µg) in 30 µl acetonitrile (ACN) and 50 µl of a 5% (w/v) solution of sodium acetate in glacial acetic acid, followed by the addition of 50 µl of an oxidant solution consisting of a 2:l ratio (v/v) of acetic acid/H 2 O 2 (30%). After the mixture was stirred at room temperature for 15 min, the residue was injected into a reversed-phase semi-preparative highperformance liquid chromatography (HPLC) column (250 × 9.6 mm, 5 μm) equipped with a 1 ml injection loop for purification. The system was operated at a flow rate of 2 ml/min with ACN/0.1 M ammonium formate (AMF) (50/50, v/v, pH = 4.5) as the mobile phase. The retention times of free iodine and the desired product were 4 and 17 min, respectively. Under these conditions, product was collected in a flask containing sterile water (50 ml). The diluted aqueous solution was passed through C18 Sep-Pak Plus (WAT020515, Waters, Milford, MA), and washed with water (20 ml). Final radioactive product [ 123 I]TZ6019
was eluted using EtOH (0.6 ml).
Radioligand binding assay
2.3.1. HEK-293-hP2X7 receptor cell culture HEK-293 cells stably transfected with the human P2X7 receptor (HEK-293-hP2X7R) were maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal calf serum, antibiotics (50 Units/ml penicillin and 50 μg/ml streptomycin) and 300 µg/ml Geneticin (Invitrogen Inc., Carlsbad, CA). Cells were grown in a 75 ml cell culture flask with a humidified atmosphere of 5% CO 2 at 37°C. Confluent HEK293-hP2X7R cells were washed twice with cold PBS, then FACS (Fluorescence Activation Cell Sorting) and western blot experiments confirmed expression of P2X7 receptor were followed as in our previous publication (Han et al., 2017) .
In vitro fluorescence assay for measurement uptake of ethidium bromide
Activation of P2X7 receptor-associated pore formation was observed using a fluorescence plate reader by measuring the cellular uptake of ethidium bromide dye in HEK-293-P2X7R cells, as reported (Chessell et al., 1997; Michel et al., 2006; Park et al., 2016) . For the actual assay,~2 × 10 5 human HEK293-hP2X7R cells per well were placed in 96-well poly-lysine coated black microplate (Corning Inc., Kennebunk, ME) overnight. The phosphate-buffered saline (PBS) consisting of 137 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 , and 2 mM KH 2 PO 4 was used for washing HEK293-P2X7 cells in the growth medium and was removed before performing the assay. Each well then was replaced with 90 μL of assay solution consisting of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (10 mM), N-methyl-D-glucamine (5 mM), KCl (5.6 mM), D-glucose (10 mM), and CaCl 2 (0.5 mM) (pH 7.4) and supplemented with 280 mM sucrose. Ten µl of 60 μM BzATP (final 6 µM), and 10 µl of 10× of the synthesized compound at serial diluted concentration (final concentration 0.3 nM-3 µM) was added to each well. After incubation for 15 min, ethidium bromide uptake was detected by measuring the fluorescence with a VictoR3 plate reader (Perkin Elmer Inc., Waltham, MA), using an excitation wavelength of 540 nm and emission wavelength of 615 nm. The results were expressed as relative to the maximum accumulation of ethidium bromide when stimulated with BzATP only, and the IC 50 values were determined using nonlinear regression by 3-parameter 
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inhibitor-effect equation in Prism (GraphPad Software, Inc., San Diego, CA). normalized to fmol/mg as described for the online internal Prism calibration procedures: http://www.graphpad.com/quickcalcs/radcalch.
Radioligand saturation binding assay
Radioligand competition binding assay using [ 123 I]TZ6019
In radioligand competition binding studies,~2 × 10 5 HEK293-hP2X7R cells were placed in 96-well poly-lysine coated microplate (Bioworld Inc., Dublin, OH) overnight. Culture medium was removed on the second day, and cells were washed three times with 250 µl/well ice-cold assay buffer (50 mM Tris-HCl pH 7.4 with 0.1% BSA). Then 80 µl/well of assay buffer, 10 µl of assay buffer with serial diluted cold GSK1482160 or TZ6019, final concentration in the range of 0.1 nM-3 µM, and 10 µl of assay buffer with fixed concentration of [ 123 I]TZ6019 (final 9.7 nM) were added. Wells without adding the testing compound were considered as the maximum bound, and wells adding 100 μM of GSK1482160 were considered as the non-specific bound. Triplicate wells were made for each concentration in the assay. The rest of the procedure was as same as the saturation binding. The specific bound counts (the nonspecific bound counts subtracted from the total observed counts) (cpm) were expressed as a percentage of the maximal bound, and then these binding data were curve-fit to a 3-parameter inhibitor-effect equation to derive the potency (IC 50 ) of the test compound in Prism (GraphPad Software, Inc, San Diego, CA). The equilibrium dissociation constant (K i ) of the test compound was calculated by the Cheng-Prusoff equation (Cheng and Prusoff, 1973) : radioactivity concentration and specific activity 1.33 GBq/µmol), and 10 µl of assay buffer with serial diluted compounds including GSK1482160 and TZ6019. The final concentration ranged from 0.1 nM to 3 µM. The binding-effect data were curve-fit to a 3-parameter inhibitor-effect equation to derive the potency (IC 50 ) of the test compound using Prism (GraphPad Software, Inc., San Diego, CA).
Mutant tau P301S mouse model
All rodent experiments were conducted in compliance with the Guidelines for the Care and Use of Research Animals under protocols approved by Washington University's Institutional Animal Care and Use Committee. P301S transgenic mice expressing the human tau P301S mutant form of human microtubule-associated protein tau (MAPT) under the direction of the mouse prion protein promoter (Prnp) and resulting in 5-fold greater human tau expression over endogenous mouse tau protein (Yoshiyama et al., 2007) . Breeding pairs were purchased from the Jackson Laboratory, and resulting progenies were maintained on a B6C3 background to generate both P301S transgenic and wild type littermate controls. Mice had access to food and water ad libitum and were housed on a 12-h light/dark cycle. Nine-month-old P301S mutant mice, along with their wild type littermates, were applied for this study.
In vitro autoradiography studies of P301S mouse brain
After saline perfusion and euthanasia of the mice, brain tissue was quickly collected and each mouse brain was cut sagittal into two parts along the midline. One half-brain was directly frozen in liquid nitrogen for post-mortem autoradiography studies; the other half was drop-fixed in 4% formaldehyde at 4°C for use in immunofluorescence microscopy studies. For autoradiography studies, 20 μm brain slices from P301S mice and wild type control mice were incubated with 2.8 MBq/ml [ 123 I]TZ6019 at room temperature for 60 min, after a 15-min pre-incubation in assay buffer (50 mM Tris-HCl buffer, pH 7.4, 0.1% BSA, and 1 mM EDTA). Following this incubation, sections were washed 2 times in assay buffer at 4°C and rinsed once using distilled water at 4°C to remove buffer salts. Then the slides were air-dried and exposed to the storage phosphor screen (Fuji Photo Film Inc., Tokyo, Japan) in an imaging cassette for 2-4 h in 4°C at dark. The distribution of radioactivity was visualized by a Fuji Bio-Imaging Analyzer FLA-7000 (GE healthcare Life Sciences Inc., Pittsburgh, PA). Photo-stimulated luminescence was quantified in one representative brain section using Multi Gauge v3.0 software (Fuji Photo Film Inc., Tokyo, Japan). Data were background-corrected and expressed as photo-stimulated luminescence signals per square millimeter (PSL/mm 2 ). For statistical comparison, the student t-test were applied using MS Excel and p < 0.05 was considered statistically significant.
Immunofluorescence (IF) microscopy
The fixed brain tissue was cut into 50 μm slices, stored free-floating in cryoprotectant solution (10% ethylene glycol, 30 mM phosphate buffer, 15% sucrose) and kept at 4°C until use. Slices were blocked at room temperature for 1 h in 5% normal horse serum (NHS) prior to incubation with the primary antibodies: P2X7 receptor (rabbit anti-P2X7 receptor polyclonal antibody, 1:50, Alomone labs Inc., Jerusalem, Israel), and GFAP (chicken anti-GFAP polyclonal antibody, 1:1000, Abcam Inc, Cambridge, MA) in 5% NHS with 1× TBS 0.1% Triton X-100 overnight at 4°C. Sections were incubated for 1 h at room temperature with fluorescent-conjugated secondary antibodies (1:1000 anti-chicken DyLight 488 and 1:1000 anti-rabbit Alex 594, ThermoFisher Scientific Inc., Waltham, MA) and counter stained with DAPI for 5 min. Sections were then mounted onto slides, and cover slipped using Fluoromount G mounting solution (Southern Biotech Inc., Birmingham, AL). The 60× confocal microscope images were collected from a Nikon A1Rsi scanning confocal microscope system in the Washington University Center for Cellular Imaging. All images were taken with the same fluorescent settings and subsequently adjusted equally for brightness and contrast to ensure accurate pathologic quantification.
Results
Chemistry
The precursor desmethyl-GSK1482160 was synthesized by following standard methods (Gao et al., 2015; Han et al., 2017 ) (Scheme 1A). The condensation of L-pyroglutamic acid with amine under 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDAC) and 1-hydrobenzotrizole (HOBt) produced product 3 in 70% yield. Then reaction of desmethyl-GSK1482160 3 with tributyl-(3-chloropropenyl)-stannane in the presence of LiHMDS gave the radiolabeling precursor 4. Iodination of precursor in chloroform afforded the standard reference 5 (TZ6019) in good yield (65%). The fluoroethyl modified compound 6 (TZ5038) was produced from 3 and 1-bromo-2-fluoroethane in similar procedure. The structure of compound 4, 5, 6 were confirmed by NMR spectroscopy and LC-MS.
Radiochemistry
The one-step iodine-123 radiolabeling of the tin precursor 4 proceeded smoothly at room temperature. Under the optimized conditions (Scheme 1B), the product was obtained in high yield (85 ± 5%, n = 8, decay corrected to the end of synthesis), excellent radiochemical purity (> 99%), and theoretical specific activity 34 GBq/µmol.
Fluorescence assay
A fluorescence assay based on the ethidium bromide measurement of the pore permeation was used to assess the binding potency of the newly synthesized iodinated compounds and other known P2X7 compounds. The known P2X7 compound GSK1482160 used as an internal control had an IC 50 value of 2.10 ± 0.30 nM, consistent with previous reports (Gao et al., 2015; Han et al., 2017) . The fluoroethyl modified compound 6, TZ5038 (9.93 ± 2.1 nM) showed slightly higher IC 50 value compared to GSK1482160 (Fig. 2, Table 1 ). The assay revealed that iodinated compounds TZ6019 had 5-fold (9.75 ± 1.2 vs 2.10 ± 0.3 nM) lower binding potency than compound GSK1482160 (Scheme 1, Table 1 ), but similar binding potency to the fluoroethyl substituted compound TZ5038, suggesting that extending the alkyl chain of pyrrolidine may interfere with the P2X7 receptor binding but the binding potency was still in nanomolar range.
Saturation binding [ 123 I]TZ6019
In the radioligand saturating binding assays, non-specific binding of [ 123 I]TZ6019 remained constant in 2-5 × 10 5 cells of HEK-hP2X7R, suggesting that the non-specific binding to the cell is minimal (Fig. 3) . The specific binding curve showed a typical saturation binding curve, with nanomolar range (K d = 19.3 ± 2.8 nM) of binding affinity (Fig. 3) . The low dissociation rate permits the washing of the plate for the separation of free from bound radioligand (Han et al., 2017; Letavic et al., 2013; Territo et al., 2016) was 262 ± 10 fmol/mg, which were consistent with the carbon-11 labeled GSK1482160 measurement from previous studies (Han et al., 2017; Territo et al., 2016) . (Fig. 2C,  D, Fig. 3A, B) and compared. The known P2X7 compound tracer uptake was significantly elevated in P301S mice (Fig. 4, Table 2 ). Different brain regions including cortex, hippocampus, thalamus and total brain were quantified and compared to wild type controls (Fig. 5 , Table 2 ). In hippocampus, P2X7 receptor was highly expressed in the P301S mice (n = 3, 255.05 ± 10.90 PSL/mm 2 ), which was 1.7-fold higher than the wild type mice group (154.18 ± 16.14 PSL/mm 2 , n = 3, P = 0.00043). Specific binding in cortex (n = 3) was 330.53 ± 91.08 PSL/mm 2 for P301S mice which was 2.4-fold higher than in wild type mice (135.23 ± 32.55 PSL/mm 2 ; P = 0.012) (Figs. 4 and 5, Table 2 ). The expression of P2X7 receptor in thalamus was also significantly higher in P301S mice than wild type mice (P = 0.039, n = 3), 337.98 ± 93.45 PSL/mm 2 for P301S and 187.41 ± 61.02 PSL/mm 2 . Finally the expression of P2X7 receptor in total brain was significantly higher in P301S mice than wild type mice (P = 0.043, n = 3), 260.86 ± 48.93 PSL/mm2 for P301S and 193.05 ± 39.92 PSL/mm2 . An overall increasing trend (P = 0.0013) was found when including all regions quantified.
Competition binding potency
Expression of P2X7 receptor and astrocytes staining in P301S mice
Immunofluorescence (IF) staining was done in the other half of the brain tissues from P301S and wild type mice. The data revealed that astrocytes (GFAP, green) colocalized with P2X7 receptor (red) in the hippocampal region as visualized by the dual labeled yellow cells (Fig. 6) . Overall, our IF microscopy results confirmed that expression of P2X7 receptor was up-regulated in brains of P301S mice, and colocalized with astrocytes.
Discussion
A number of radiolabeled P2X7 ligands have been reported (Donnelly-Roberts et al., 2009; Han et al., 2017; Honore et al., 2006; Janssen et al., 2014; Lord et al., 2015; Ory et al., 2016; Territo et al., 2016) (Fig. 1) receptor binding with these radioligands (Lord et al., 2015) . GSK1482160 was originally discovered from GlaxoSmithKline with a high throughput screening for P2X7 receptor specific antagonists (Abdi et al., 2010; Chambers et al., 2010) . Continuing the work on the C-11 labeled analogue, we synthesized and characterized the iodinated analogue TZ6019 in this study. We observed that the binding potency of TZ6019 was in nanomolar range. We applied both has significantly higher specific binding in P301S mice (Figs. 4 and 5) . This suggests that [ 123 I]TZ6019 may be used to assess neruroinflammatory response in AD or tauopathy. The expression of P2X7 receptor in P301S mouse brain was globally increased, particularly in hippocampus, cortex, and thalamus ( Table 2 ). The IF results further support that the P2X7 receptor elevation in hippocampus, associating with an increased activation of astrocytes in P301S mice (Fig. 6) .
These results agree with previous report for astrocytic activation in P301S mice, but previous studies did not measure the P2X7 receptor expression (Lopez-Gonzalez et al., 2015) . In mouse models of AD, Fig. 4 astrocytes or microglia exhibit abnormal activation and produce proinflammatory mediators (Lopez-Gonzalez et al., 2015; Parvathenani et al., 2003) . P2X7 receptor plays a vital role in astrocytes/microgliamediated IL-1β processing and release through the membrane receptors, which promotes inflammatory damage in CNS (Grygorowicz et al., 2016; Jimenez-Pacheco et al., 2016) . The elevated expression of P2X7 receptor in AD mice model of tg2576 mice was reported (Parvathenani et al., 2003) , but the expression of P2X7 receptor in a (Han et al., 2017; Ory et al., 2016) . Understanding the interaction of P2X7 receptor with its ligands is key to developing therapeutic strategies targeting this receptor. However the weak binding affinity to rodent P2X7 receptor may limit the application of this radiotracer (Gao et al., 2015; Han et al., 2017; Ory et al., 2016) . Additional new radioligands are still needed in the future. Compared to compound GSK1482160, the fluoroethane or iodinated modification showed similar binding potency to P2X7 receptor with minor reduction of binding potency based on IC 50 values. In vivo binding specificity is a key parameter for a novel radiotracer. Without using P2X7 receptor knockout mice to characterize the in vivo binding specificity of [
123 I]TZ6019 was a limitation. Our future study of promising P2X7 receptor radiotracers will use P2X7 receptor knockout mice to confirm their in vivo binding specificity. Nevertheless, the properties of [ 123 I]TZ6019 reported in current study will facilitate the development of new selective P2X7 ligands for potential imaging and therapeutic applications.
Conclusion
A potent iodinated radiotracer [ 123 I]TZ6019 for P2X7 receptor was successfully radiosynthesized and evaluated in this study. Our in vitro cell binding assays demonstrated that this radioligand specifically binds to recombinant human P2X7 receptor with nanomolar affinity. Our in vitro autoradiography revealed that [ 123 I]TZ6019 was able to detect the increase of P2X7 receptor expression in brain from P301S mutant transgenic mice. This compound represents a promising radioligand for screening new P2X7 compounds and assessing P2X7 receptor expression in neuroinflammatory related diseases.
